POS0933

TREATMENT ACCESS AND ADHERENCE DURING SOCIAL PREVENTIVE AND MANDATORY ISOLATION IN ARGENTINIAN PATIENTS WITH SPONDYLOARTHRITIS

C. Airolidi¹, V. Martire², M. S. Gálvez Elkin³, P. Girard Bosch², V. Duarte⁴, S. Scarafia⁵, F. Sommerfleck⁶, M. Machado Escobar⁷, N. Callahuara⁸, J. Alcivar Navarrete⁹, M. A. Medina⁹, E. Buschiazio¹⁰, M. Cosatti¹¹, R. Garcia Salinas¹², E. Saturansky⁶, V. Cosentino¹³, D. Vila¹⁴, M. J. Gamba¹⁵, E. Kerzberg¹³, G. P. Pendon¹⁶, D. Zelaya¹³, R. Águila Maldonado¹⁷, L. Abbas¹⁸, R. Nieto¹, S. Nási¹⁹, R. Luis¹³, M. L. Acosta Felquer²⁰, M. Benegas⁸ on behalf of Grupo de estudio de la Sociedad Argentina de Reumatología de Espondiloartritis axial y Artritis reactiva (GESAR EspAax-ARE). ¹Hospital Provincial, Rheumatology, Rosario, Argentina; ²Instituto Médico Platense, Rheumatology, La Plata, Argentina; ³Instituto Cardiológico Santiago del Estero, Rheumatology, Santiago del Estero, Argentina; ⁴Monte Grande Clinic, Rheumatology, Buenos Aires, Argentina; ⁵Hospital Municipal San Cayetano, Rheumatology, Buenos Aires, Argentina; ⁶Hospital Mendez, Rheumatology, Buenos Aires, Argentina; ⁷Hospital Eva Perón, Rheumatology, Tucumán, Argentina; ⁸Hospital Rivadavia, Rheumatology, Buenos Aires, Argentina; ⁹Hospital Tornú, Rheumatology, Buenos Aires, Argentina; ¹⁰Hospital Sr. Del Milagro, Rheumatology, Salta, Argentina; ¹¹CEMIC, Rheumatology, Buenos Aires, Argentina; ¹²Hospital Italiano de La Plata, Rheumatology, La Plata, Argentina; ¹³Hospital Ramos Mejía, Rheumatology, Buenos Aires, Argentina; ¹⁴Centro Médico Ginecológico, Rheumatology, Buenos Aires, Argentina; ¹⁵Hospital Posadas, Rheumatology, Buenos Aires, Argentina; ¹⁶Hospital Ricardo Gutierrez, Rheumatology, La Plata, Argentina; ¹⁷Hospital San Martín, Rheumatology, La Plata, Argentina; ¹⁸PSORIAHUE, Rheumatology, Buenos Aires, Argentina; ¹⁹Hospital El Carmen, Rheumatology, Mendoza, Argentina; ²⁰Hospital Italiano de Buenos Aires, Rheumatology, Buenos Aires, Argentina

Background: Access to high-cost treatments is especially limited in low-resource countries. This issue is becoming stronger today given the health and economic crisis caused by the SARS-CoV2 pandemic. There are no reports in our country on limitations to access and adherence to treatment in patients with Spondyloarthritis (SpA) during social preventive and mandatory isolation.

Objectives: Evaluate access and adherence to treatment in patients with Spondyloarthritis during social preventive and mandatory isolation.

Methods: Patients with axial spondyloarthritis (axSpA) radiological (r-axSpA), non-radiological (nr-axSpA) and peripheral spondyloarthritis (pSpA), according to ASAS criteria and psoriatic arthritis (PsA) according to CASPAR criteria, were included. Sociodemographic data, comorbidities, disease activity and treatments were collected at baseline. Data on treatment discontinuation, medical attention for suspected COVID-19 disease, RT-qPCR for SARS-CoV-2 detection and outcome of COVID-19 disease were collected from April to September 2020. Numerical variables were summarized as means and standard deviations (SD) or as medians and interquartiles 25-75 (IQ 25-75).

Results: 320 patients were included, 55% were male, with a mean age of 50 years (SD 13), 21.6% had diagnosis of r-axSpA, 6.9% nr-axSpA, 6.9% pSpA, and 64.7% PsA. Disease duration was 11 (IQ 5-16) years and activity parameters were as follow: BASDAI 3.65 (SD 3), BASFI 3 (1.5-9), PASI 0.3 (0-7), BSA 0.2 (0-6). 14 (4.4%) patients with COVID-19 disease were reported, 10 were confirmed by positive RT-qPCR and 4 by symptoms and history of close contact with SARS patients. 4 (28.6%) received anti TNF (3 adalimumab, 1 certolizumab), 4 (28.6%) anti IL17 (3 secukinumab and 1 ixekizumab), 8 (57%) methotrexate (MTX) and 2 (14%) leflunomide (LF). Among the 320 patients included, 59 (18.4%) discontinued at least one treatment during follow-up. The discontinued medications were: adalimumab (16), MTX (15), secukinumab (9), etanercept (6), certolizumab (4), ustekinumab (3), NSAIDs (2), apremilast (1), golimumab (1), ixekizumab (1), LF (1), MTX plus LF (1). The main reason for treatment discontinuation was drug shortage: 36 (62%), followed by patient's decision: 12 (21%) and medical indication: 11 (17%). Of the 36 patients who discontinued due to shortage, 11 received adalimumab, 8 secukinumab, 5 MTX, 3 etanercept, 3 certolizumab, 3 ustekinumab, 2 NSAIDs and 1 golimumab.

Conclusion: In our Argentinian cohort of patients with SpA, drug shortage was the main reason for treatment discontinuation. The SARS-CoV2 pandemic exposed limitations to access to treatment for patients with SpA.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.3147

POS0934

BIOLOGICAL THERAPY IN UVEITIS ASSOCIATED TO AXIAL SPONDYLOARTHRITIS. SINGLE CENTER UNIVERSITY STUDY

A. Herrero-Morant¹, I. González-Mazón¹, V. Calvo-Río¹, J. Rueda-Gotor¹, M. Á. González-Gay¹, R. Blanco¹. ¹Hospital Universitario Marqués de Valdecilla, Rheumatology, Santander, Spain

Background: Uveitis is the most frequent extraarticular manifestation of axial Spondyloarthritis (axSpA). Effects of Biological Therapy (BT) on uveitis associated to axSpA are contradictory (1-3).

Objectives: To assess in uveitis associated to axSpA a) frequency and features of uveitis, and b) efficacy and relation of BT in a single-center university study.

Methods: Observational study from a cohort of 301 consecutive unselected patients with axSpA classified according to the Assessment of SpondyloArthritis International Society criteria. Episodes of uveitis were analyzed before and after BT initiation. Likewise, uveitis incidence rate (episodes/100 patients/year) at baseline and after first BT was calculated.

Results: Uveitis was observed in 44 (25 men/19 women) out of 301 (14.6%) patients. Mean age was 45.6 ± 10.3 years. Demographic and clinical features in patients who developed uveitis and those that did not are summarized in Table 1. After 18.6 ± 10.4 years of follow-up, 44 (14.6%) patients suffered from at least one episode of uveitis. Uveitis was anterior and acute in all cases and unilateral in 37 (84.1%) patients. Mean anterior chamber cells was 1.7 ± 1.2 cells.

Per episode of uveitis, 20 patients received BT with: secukinumab (SECU) (n=7, 35%), adalimumab (n=6, 30%), golimumab (n=3, 15%), infliximab (n=2, 10%), certolizumab (n=1, 5%), and etanercept (ETN) (n=1, 5%). Before the initiation of BT, patients treated with SECU developed 29.7 episodes/100 patients/year while those treated with monoclonal anti-TNFα 16.3 episodes/100 patients/year and patients with ETN 5.8 episodes/100 patients/year. After 5.9 ± 3.7 years of follow-up, patients treated with SECU developed 16.1 episodes/100 patients/year while those treated with monoclonal anti-TNFα 7.6 episodes/100 patients/year and patients with ETN 0 episodes/100 patients/year (Figure 1). No serious adverse effects were observed.

Conclusion: Uveitis was observed in 14.6% of axSpA. Most of them were HLA-B27 positive. Acute, anterior and unilateral was the most frequent pattern of uveitis in axSpA. There was a similar decrease in incidence rate between patients treated with SECU and those treated with monoclonal anti-TNFα.

REFERENCES:

- Deodhar AA, et al. ACR Open Rheumatol. 2020; 2:294-299.
- Roche D, et al [abstract]. Arthritis Rheumatol 2019; 71 (suppl 10).
- Lindström U, et al Annals of the Rheumatic Diseases 2020;79:9-10.

Table 1. Main general features and differences between patients with and without uveitis.

	Overall n= 301	Uveitis n= 44	Non uveitis n= 257	p
Age, years (mean±SD)	44.9 ± 11.8	45.6 ± 10.3	44.8 ± 12.1	0.47
Gender, n (m/w) (%)	179/122 (59.5/40.5)	25/19 (56.8/43.2)	154/103 (59.9/40.1)	0.71
HLA-B27 positive, n (%)	190 (63.1)	37 (84.1)	153 (60.0)	0.00
Follow-up of axSpA, year (mean±SD)	13.5 ± 11.2	18.6 ± 10.5	12.6 ± 11.1	0.33
Family history, n (%)	84 (27.9)	15 (34.1)	69 (27.2)	0.35
r-axSpA, n (%)	217 (72.1)	36 (81.8)	181 (70.4)	0.12
nr-axSpA, n (%)	84 (27.9)	8 (18.2)	76 (29.6)	0.12
Enthesitis, n (%)	108 (35.9)	14 (31.8)	94 (36.6)	0.54
Peripheral arthritis, n (%)	96 (31.9)	12 (27.3)	84 (32.7)	0.47
Psoriasis, n (%)	35 (11.6)	6 (13.6)	29 (11.3)	0.65
Inflammatory bowel disease, n (%)	22 (7.3)	2 (4.5)	20 (7.8)	0.45
Hip involvement, n (%)	20 (6.6)	3 (6.8)	17 (6.6)	0.96
Dactylitis, n (%)	17 (5.7)	3 (6.8)	14 (5.4)	0.72
Cardiovascular event, n (%)	7 (2.3)	1 (2.3)	6 (2.3)	0.98

Figure 1. Uveitis incidence rate before and after biological therapy.

Disclosure of Interests: Alba Herrero-Morant: None declared, Iñigo González-Mazón: None declared, Vanesa Calvo-Río Speakers bureau: Abbott, Lilly, Celgene, Grünenthal, UCB Pharma, Grant/research support from: MSD and Roche, Javier Rueda-Gotor: None declared, Miguel Á. González-Gay Speakers bureau: AbbVie, Pfizer, Roche, Sanofi, Lilly, Celgene and MSD, Grant/research support from: AbbVie, MSD, Jansen and Roche, Ricardo Blanco Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, Sanofi, Lilly and MSD, Grant/research support from: AbbVie, MSD and Roche

DOI: 10.1136/annrheumdis-2021-eular.3229

POS0935

DO PERIPHERAL AND EXTRA MUSCULOSKELETAL MANIFESTATIONS HAVE AN IMPACT ON BIOLOGIC DMARD PRESCRIBING PATTERNS IN AXIAL SPONDYLOARTHRITIS: THE RESULTS OF TREASURE EXPERIENCE

E. Durak Ediboglu¹, D. Solmaz¹, O. Karadag², Y. Pehlivan³, M. Çınar⁴, A. İ. Erteli², B. N. Coşkun³, D. Ersöz⁵, O. Küçükşahin⁶, A. Ateş⁷, S. Kiraz², B. Yağiz³, E. Tekgoz⁴, H. Emmungil⁸, E. Gönüllü⁹, G. Kabadayı¹, T. Kaşifoğlu¹⁰, R. Mercan¹¹, G. Kimyon¹², S. Colak⁴, C. Bes¹³, N. S. Yasar Bilge¹⁰, V. Yazısız¹⁴, S. S. Koca¹⁵, P. Atagündüz¹⁶, N. A. Kanitez¹⁷, U. Kalyoncu², S. Akar¹. ¹Izmir Katip Çelebi University, Rheumatology, Izmir, Turkey; ²Hacettepe University, Rheumatology, Ankara, Turkey; ³Uludağ University, Rheumatology, Bursa, Turkey; ⁴University of Health Sciences, Gulhane Faculty of Medicine, Rheumatology, Ankara, Turkey; ⁵University of Health Sciences, Adana Education and Research Hospital, Rheumatology, Adana, Turkey; ⁶Yıldırım Beyazıt University, Rheumatology, Ankara, Turkey; ⁷Ankara University, Rheumatology, Ankara, Turkey; ⁸Trakya University, Rheumatology, Edirne, Turkey; ⁹Sakarya University, Rheumatology, Sakarya, Turkey; ¹⁰Osmangazi University, Rheumatology, Eskişehir, Turkey; ¹¹Namık Kemal University, Rheumatology, Tekirdağ, Turkey; ¹²Mustafa Kemal University, Rheumatology, Hatay, Turkey; ¹³Sadi Konuk Education and Research Hospital, Rheumatology, Istanbul, Turkey; ¹⁴Akdeniz University, Rheumatology, Antalya, Turkey; ¹⁵Firat University, Rheumatology, Elazığ, Turkey; ¹⁶Marmara University, Rheumatology, Istanbul, Turkey; ¹⁷Koc University, Rheumatology, Istanbul, Turkey

Background: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease mainly affecting sacroiliac joints and spine. Peripheral arthritis, dactylitis and enthesitis may also occur. Extra musculoskeletal manifestations (EMMs; uveitis [AAU], inflammatory bowel disease [IBD] and psoriasis [Pso] are among the most common ones) are important features and might have an impact on the disease burden in patients with axSpA. The presence of EMM, in particular IBD and AAU could influence the choice of TNFi however little is known regarding the role of peripheral manifestations together with the EMM on the prescribing patterns in axSpA patients.

Objectives: To examine the frequency of peripheral and EMMs in a real-world axSpA cohort and their effect on the choice of first advanced treatment.

Methods: In total 1687 axSpA patients (58% male and the mean age (±SD) was 38.5 ± 10.9) who initiated his/her first biologic were included in the present analysis. The data for the current study was obtained from the TReasure web-based registry; in which RA and SpA patients treated with bDMARDs from different regions of Turkey. Baseline demographic, disease related characteristics, peripheral and EMMs were extracted. Characteristics of patients with and without peripheral/extra-musculoskeletal involvement were compared as well as factors/covariates associated with the choice of first TNFi and secukinumab was analysed.

Results: Enthesis (28.2%) was found the most common peripheral manifestations and peripheral arthritis (26.4%) and hip arthritis (24.4%) followed it. Symptom duration to the first advanced treatment initiation was significantly shorter in axSpA patients with peripheral arthritis, enthesitis, dactylitis and psoriasis and longer in hip arthritis and AAU. HLA-B27 positivity was significantly lower in patients with arthritis, psoriasis and IBD and higher with hip arthritis and AAU. In multivariate analysis the presence of IBD is significantly associated with the preference of monoclonal TNFi (mab) over etanercept (ETA) (OR 5.770; 95%CI 1.788-18.616). However ETA was preferred in patients with hip arthritis ($p=0.003$), longer symptom duration ($p=0.049$), and using sulfasalazine ($p=0.043$). In comparison with mabs, secukinumab (SEC) prescription was found to be significantly associated with higher age ($p=0.001$), sulfasalazine ($p=0.001$) and methotrexate usage ($p=0.053$) among axSpA patients need their first advanced treatment.

Conclusion: The results of the current study confirm the pathophysiologic associations of peripheral involvement and EMM in axSpA patients. Apart from hip arthritis the presence of IBD has an impact on the prescription of advanced treatment in real-life.

Table 1. Clinical characteristics of patients in cohort

	All patients (n=1678)	Peripheral arthritis (n=445)	Dactylitis (n=81)	Enthesis (n=476)	Uveitis (n=193)	Psoriasis (n=152)	IBD (n=78)	Hip involvement (n=412)
Age, mean±SD	38,5±10,9	38,3±11,6	37,4±11,1	37,9±10,7	41,3±11,4	39,9±11,3	41,6±12,2	39,2±11,2
Male sex, n (%)	974 (57,7)	184 (41,3)	34 (42)	238 (50)	96 (49,7)	54 (35,5)	43 (55,1)	272 (66)
Symptom duration, mean month±SD	108,5±98,9	96,9±92,9	79,1±76,5	100,4±92,7	144,7±110,2	87,7±94	94,5±98	133,3±108,2
HLA B27 positivity, n (%)	621 (53,7)	142 (46,3)	27 (51,9)	174 (49,4)	104 (77)	34 (36,2)	16 (27,1)	186 (59,8)
Concomitant cDMARD usage (yes), n (%)	420 (24,9)	170 (38,2)	39 (48,1)	133 (27,9)	53 (27,5)	58 (38,2)	24 (30,8)	99 (24)
BASDAI, mean±SD	5,1±2,5	5,1±3	5,3±3,1	5,3±2,9	4,7±2,5	5,6±2,4	4,8±2,3	5,3±2,1
ASDAS-CRP, mean±SD	3,1±1,5	2,6±1,9	2,5±1,8	2,8±1,7	2,9±1,7	3,4±1,3	3,1±1,5	3,7±1,4

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.3236

POS0936

TREATMENT OF ANKYLOSING SPONDYLITIS WITH TUMOR NECROSIS FACTOR-ALPHA INHIBITORS LOWERS THE RISK OF RENAL FUNCTION DECLINE

S. J. Lee¹, J. S. Lee¹, U. C. Cha¹, E. J. Nam¹. ¹School of Medicine, Kyungpook National University, Korea, Internal Medicine, Daegu, Korea, Rep. of (South Korea)

Background: Ankylosing spondylitis (AS) is associated with reduced renal function, possibly due to chronic inflammation or the use of nephrotoxic drugs. However, the long term effect of tumor necrosis factor (TNF) inhibitors on renal function in patients with AS has not been well established.

Objectives: We therefore investigated the association of TNF inhibitors treatment and change in estimated glomerular filtration rate (GFR) using the Korean College of Rheumatology Biologics (KOBIO) registry (ClinicalTrials.gov, NCT01965132), a prospective nationwide biologics registry.

Methods: We enrolled 1846 patients with AS in KOBIO registry and as disease controls, 471 patients with AS who did not take biologics in Kyungpook National University Hospital. The estimated glomerular filter rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) equation was evaluated in both groups. Renal insufficiency was defined as eGFR <60mL/min/1.73 m². Changes and differences of eGFR in each group were assessed at every follow-up year using paired t-test. Risk factors for renal function decline were identified using multivariable analysis.

Results: The changes of eGFR values in patients treated with TNF inhibitors were not significantly decreased during 5 years follow up period. However, those in patients not treated with TNF inhibitors were significantly decreased. Moreover, among patients with renal insufficiency, use of TNF inhibitors did not affect further renal function deterioration during follow up period. Using multivariable logistic regression models, patients treated (versus not treated) with TNF inhibitors had a lower risk of renal function decline after 5 years follow up period ($p<0.045$).

Conclusion: The use of TNF inhibitors was independently associated with lower risk of renal function decline and TNF inhibitors may be a safe treatment option in AS patients with renal insufficiency.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.3605

POS0937

TREATMENT SURVIVAL ON BIOLOGICS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS – DATA FROM MOSCOW UNIFIED ARTHRITIS REGISTRY (MUAR)

K. Lytkina¹, E. Koltsova², E. Rozochkina³, E. Shmidt⁴, G. Lukina^{3,5}, A. Zagrebneva^{6,7}, E. Zhilyaeva^{8,9}. ¹City Clinical Hospital#4, Rheumatology Department, Moscow, Russian Federation; ²Rheumatology Research Institute of the Organization of Health and Healthcare Management, The Organizational-Methodical Division, Moscow, Russian Federation; ³A.S. Loginov Moscow Clinical Scientific Center, Rheumatology Department, Moscow, Russian Federation; ⁴department City Clinical Hospital 1 named after N.I. Pirogov, Rheumatology Department, Moscow, Russian Federation; ⁵V.A. Nasonova Research Institute of Rheumatology, Rheumatology, Moscow, Russian Federation; ⁶City Clinical Hospital 52, Rheumatology, Moscow, Russian